Close

Nuclear

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

As the antoantigen, nuclear is one of the most common targets of autoimmune response. Autoantigens are released from secondary necrotic cells and from NETosis, a form of cell death in which neutrophils extrude DNA and other nuclear and cytoplasmic material from the cell, with defective degradation of resulting DNA-containing neutrophil extracellular traps (NETs).
  • CAR Vector Products

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAART-LX135 Anti-Nuclear (71F12) h(CD28-CD3ζ) CAART, pCDCAAR1 Human 71F12 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX136 Anti-Nuclear (121G9) h(CD28-CD3ζ) CAART, pCDCAAR1 Human 121G9 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX137 Anti-Nuclear (J3.4) h(CD28-CD3ζ) CAART, pCDCAAR1 Mouse J3.4 Mouse scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX138 Anti-Nuclear (J9.11) h(CD28-CD3ζ) CAART, pCDCAAR1 Mouse J9.11 Mouse scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX139 Anti-Nuclear (71F12) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human 71F12 Human scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX140 Anti-Nuclear (121G9) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human 121G9 Human scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX141 Anti-Nuclear (J3.4) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Mouse J3.4 Mouse scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX142 Anti-Nuclear (J9.11) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Mouse J9.11 Mouse scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.